Summary
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 10, 2026, to announce its financial results for the fourth quarter of 2025. While the 8-K itself is brief and primarily serves to incorporate the details from a furnished press release (Exhibit 99.1), the core information pertains to the company's performance in the latest reported quarter. Investors should review the accompanying press release for specific figures on revenue, profitability, and any forward-looking guidance provided by the company.
Key Highlights
- 1The 8-K filing announces Edwards Lifesciences' financial results for the fourth quarter of 2025.
- 2Specific financial performance details are contained within the furnished press release (Exhibit 99.1).
- 3The press release, dated February 10, 2026, is incorporated by reference into the 8-K.
- 4The filing was made on February 10, 2026, following the event date of February 9, 2026.
- 5Information furnished under Item 2.02 is not considered 'filed' for the purposes of the Securities Exchange Act of 1934.
- 6The report includes the Cover Page Interactive Data File in its exhibits.
Frequently Asked Questions
The actual financial results for the fourth quarter of 2025 are detailed in the press release dated February 10, 2026, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.
When information is 'furnished' under Item 2.02 of an 8-K, it means the company is providing it to the SEC, but it does not carry the same legal implications of being 'filed' under the Securities Exchange Act of 1934. This often means that forward-looking statements within the furnished document are subject to safe harbor provisions.
The press release typically includes key financial metrics such as revenue, earnings per share (EPS), net income, and often provides management commentary on performance drivers, strategic updates, and potentially financial guidance for future periods.